Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis

BACKGROUND: Delanzomib, a novel proteasome inhibitor, has demonstrated promising efficacy and antitumor ability in human multiple myeloma cell lines and patient‐derived cells. However, the potential therapeutic effects of delanzomib on breast cancer remain unknown. In this study, we show that delanz...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mopei, Liang, Li, Lu, Jiaxiong, Yu, Yang, Zhao, Yanling, Shi, Zhenfeng, Li, Hui, Xu, Xin, Yan, Yuxian, Niu, Yan, Liu, Zhentao, Shen, Lin, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449274/
https://www.ncbi.nlm.nih.gov/pubmed/30883017
http://dx.doi.org/10.1111/1759-7714.13030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449274/
https://www.ncbi.nlm.nih.gov/pubmed/30883017
http://dx.doi.org/10.1111/1759-7714.13030

Ejemplares similares